Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of COVID-19 mRNA Vaccine in Individuals with Previous Adverse Reaction
NCT05212610Phase 4Completed
- Sponsor
- University of Michigan
- Start
- Mar 2022
- Primary completion
- Mar 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of tozinameran, elasomeran in coronavirus disease 2019 (COVID-19), sponsored by University of Michigan. Started Mar 2022; status: completed.
02
Drugs
tozinameranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05212610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212610.